New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.
Opinion|Podcasts|May 2, 2024
Exploring Procedural Treatments for Dry Eye
Listen
0:00 / 0:00
Experts discuss treating dry eye with procedural therapies, focusing on common in-office and at-home treatments.
Advertisement
1:00 Dry eye evaluation
4:00 Dry eye practice
9:00 Initial exam and tests
17:00 Choosing a procedure
25:00 Dry eye procedures
37:00 Creating treatment value
Advertisement
Related to this article
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.
Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
Advertisement
Advertisement
Trending on HCPLive
1
Second-Line Therapy in Fibrillary GN: Secondary Causes and Rituximab Data
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Tips on Optimizing HS Biologics, Combinations, and Surgery
4
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
5